New hope for lung cancer: experimental drug ZG006 takes on chemo

NCT ID NCT07189455

Recruiting now Disease control Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 3 trial compares a new drug called ZG006 with standard chemotherapy in 420 people whose small cell lung cancer has returned. The main goal is to see if ZG006 helps patients live longer. Participants will receive either ZG006 or one of several chemo options chosen by their doctor.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ZG006 (an experimental drug given by IV infusion)
What this could lead to: If successful, ZG006 could offer a new treatment option that helps people with relapsed small cell lung cancer live longer.
What could go wrong: This is an early Phase 3 trial, so results are not guaranteed. The drug may not work better than chemotherapy and could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SMALL CELL LUNG CANCER

Contacts and locations

Locations

Shanghai Chest Hospital
RECRUITING

Shanghai, Shanghai Municipality, 200030, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.